Real Hydrafacial Results
Evolutionary solution. Revolutionary results.
ariessence pure PDGF+ is a cutting-edge topical solution for skin rejuvenation. It is a quick, easy, consistent, and trusted approach to post-procedure skin rejuvenation. It's guaranteed to give you joy and confidence through the appearance of healthier, more vibrant skin.
We use innovative techniques to stimulate your own cells to regenerate and repair themselves. This can mean:
- Smoother, younger-looking skin
- Reduced sun damage
- Improved volume and definition
an Anti-Wrinkle Botox Competitor
The FDA has approved Daxxify by Revance, a new injectable medicine for smoothing facial wrinkles in adults. Daxxify is in the same class of medicines as Botox, Dysport, Xeomin, and Jeuveau, but may be more effective in reducing wrinkles for longer periods of time. In clinical trials, 80% of participants had little or no visible facial wrinkles after four months of using Daxxify, and half still had little evidence of wrinkles after six months. Dermatologists believe Daxxify will change the market for neuromodulators.
Before
2 Weeks
6 Months
9 Months
Before
2 Weeks
6 Months
9 Months
pure PDGF+ is the next generation of growth factor.
Pure
The power of a naturally occurring growth factor in a topical solution with only four ingredients.
Potent
Over 1,000x-300,000x the amount of growth factor of other aesthetic products.
Predictable
Pharmaceutical-grade PDGF. Provides a high-quality and consistent product, every time.
Proven
4 FDA approved medical treatments and over 5 million patients have been treated with PDGF products in the last 15 years.
*GEM 21™, Augment™, Augment Injectable™, and Regranex™.
For more information, visit https://ariessence.com/
Why choose Skiin?
Follows all CDC guidelines being committed to your safety
Most experienced skin health experts in the industry
Committed to continuous education with some of the worlds finest doctors
Recipient of Medical Aesthetics magazine as the best loyalty program
Board-certified plastic surgeon on-premise